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Nitric oxide (NO)-donor antioxidants are a class of polyvalent drugs which is focus of great interest 
today; they are potentially useful for the treatment of many forms of cardiovascular diseases, 
including the myocardial ischemia/reperfusion (I/R) damage which seems to be due to both a burst 
of reactive oxygen species (ROS) and a reduced release of NO during reperfusion. In this paper the 
results of a study on the ability of new NO-donor antioxidants containing the phenol vitamin E 
substructure and furoxan moiety to attenuate I/R damage are reported. The compounds under study 
are obtained by combining the phenol moiety (6-hydroxy-2,2,5,7,8-pentamethylchroman) present in 
vitamin E with differently substituted furoxan substructures endowed with different capacity of NO-
release. Their antioxidant and NO-dependent vasodilator activity are reported. The I/R experiments 
were performed on isolated rat heart preparations perfused at constant flow. After 20 min of 
stabilization, global ischemia was obtained by interrupting the perfusion for 30 min. After ischemia 
the hearts were reperfused for 2 hrs. The compounds were added to the perfusion buffer during the 
first 20 min of reperfusion. At the end of each experiment, infarct size was measured with nitro-blu 
tetrazolium. From the results it appears that the limitation of the infarct area is favoured by an 





Some experimental evidence supports the notion that a burst of reactive oxygen species contributes 
significantly to myocardial ischemia/reperfusion (I/R) injury. This increase in ROS concentration 
occurs during the first few minutes after ischemic tissue is reoxygenated and it is principally due to 
the interaction of oxygen with the damaged mitochondrial respiratory chain, with the consequent 
overproduction of superoxide anion (O2
-.
) [1-3]. The massive production of this radical can also be 
generated by other pathways involving xanthine oxidase, NADPH-oxidase and the arachidonic acid 
cascade [4]. Anion superoxide under the catalysis of superoxide dismutase (SOD) is transformed 
into hydrogen peroxide (H2O2), which, in the presence of metal ions, rapidly reacts with O2
-.
 
affording the very reactive and toxic hydroxyl radical (OH
⋅
) (Haber-Weiss reaction). The hydroxyl 
radical induces lipidic peroxidation, protein and DNA damage and mitochondrial alteration [5]. It 
has been shown that a number of antioxidants are able to display protection against cardiomyocyte 
disturbance during I/R, in cultured cell and animal models [6-8]. Endogenous nitric oxide (NO) 
produced by endothelial cells (EDRF) exerts a variety of physiological effects that control the 
vascular homeostasis, among these vasodilation, inhibition of platelet aggregation, attenuation of 
leukocyte adherence and aggregation, and inhibition of vascular smooth muscle cell proliferation. 
All of them can be dramatically affected by I/R [9]. It is known that I/R causes an impairment of 
endothelial function characterized by the reduced production of NO. Administration of NO or NO-
donors immediately before ischemia or at the time of reperfusion can reduce the irreversible 
myocardial injury, as well as it is known that NO reduces lesion size in experimental cerebral 
infarct [9-11, 12]. The results of these studies are frequently in conflict, this depends on the species 
of animals and on the kind of NO-donor used [10]. Interesting attempts to limit myocardial 
reperfusion injury have been done using a combination of NCX-4016 (3-[nitrooxymethyl]phenyl 2-
(acetyloxy)benzoate) and a number of antioxidants as well as resveratrol, a natural antioxidant 
poliphenol found in grapes and wine, which is able to inhibit low density lipoprotein (LDL) 
oxidation, block platelet aggregation and induce NO production [7, 13]. However, these compounds 
were infused before a prolonged ischemia. This pharmacological treatment in the clinical setting of 
acute myocardial infarction cannot be exploited because of the unpredictability of myocardial 
infarction. 
Recently we described a new class of polyvalent drugs deriving from the combination of 
antioxidants, such as phenols [14], melatonin [15] and ascorbic acid [16] with appropriate NO-
donor moieties. These products show a widely modulated balance between NO-donor and 
antioxidant properties and are potentially useful for the treatments of many forms of cardiovascular 
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diseases including myocardial I/R damage. In this paper we report the results of a study on the 
ability of compound 1 to attenuate the infarct size occurring in isolated rat hearts reperfused after 
induction of ischemia (Chart 1). We previously obtained this product [14] by combining the phenol 
moiety (6-hydroxy-2,2,5,7,8-pentamethylchroman (4) (Chart 1)) present in vitamin E, with the 
furoxancarboxamide substructure present in CAS 1609, an oral active NO-dependent vasodilator 
developed by Cassella Hoechst Company [17], and in its nitrogen containing analogue 1a (Chart 1). 
CAS 1609 proved to be able of alleviating the irreversible myocardial I/R injury when tested in vivo 
on dogs [10]. Compounds 2, 3 containing NO donor moieties related to the simple furoxans 2a, 3a 
(Chart 1), are also considered for a comparison. 
 
2. Materials and methods 
 
2.1 Chemicals 
All the chemicals used for preparing the buffer solutions and compound 4 were purchased from 
Sigma (St. Louis- MO-USA). The reagents necessary to assess myocardial infarction were 
purchased from Merck (Darmstadt- Germany). Compounds 1, 3, 1a, 2a, 3a were synthesised 
according to methods reported in literature [14, 15]. Compound 2 (2,5,7,8-tetramethyl-2-[(3-
phenylfuroxan-4-yl-oxy)methyl]chroman-6-ol) was prepared according to the procedure reported 
below. Analysis (C, H, N) of the new compound was performed by REDOX (Monza, Italy) and the 
results are within ±0.4% of the theoretical. 
To the solution of [6-(methoxyethoxymethoxy)-2,5,7,8-tetramethyl-3,4-dihydro-2H-chroman-2-
yl]methanol [14] (0.49 g, 1.50 mmol) in THF dry (15 mL) placed under positive N2 pressure NaH 
(70 mg, 1.75 mmol) was added at r.t. and the reaction was vigorously stirred for 30 min. Then 4-
benzensulfonyl-3-phenylfuroxan (0.46 g, 1.50 mmol) was added and the reaction was stirred at r.t. 
for 3 h. After that time the reaction mixture was poured into H2O (50 mL) and extracted with 
EtOAc (2×25 mL). The organic solvent was washed with brine, dried and evaporated. The resulting 
colourless oil was purified by flash chromatography (eluent 85/15 PE/EtOAc v/v) to give a 
protected compound as a colourless oil. The obtained oil was immediately dissolved in CH2Cl2 (20 
mL) and CF3COOH (2 mL) was added at r.t. The reaction mixture was stirred for 2 h, then the 
organic solvent was washed with H2O (3×20 mL), brine, dried and evaporated. The obtained oil was 
purified by flash chromatography (eluent 9/1 PE/EtOAc v/v) to give a title compound as a white 




H (CDCl3) δ: 1.45 (s, 3H, CH3), 1.89 – 2.15 (m, 11H, 
3ArCH3 + 3-H2), 2.69 – 2.73 (m, 2H, 4-H2), 4.27 (s, 1H, OH), 4.46 – 4.54 (m, 2H, CH2O), 7.47 – 
7.51 (m, 3H), 8.10 – 8.18 (m, 3H) (C6H5); NMR 
13
C (CDCl3) δ: 11.3, 11.8, 12.2, 20.2, 21.9, 28.9, 
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73.3, 74.8, 107.6, 116.9, 118.6, 121.4, 122.4, 122.8, 126.1, 128.9, 130.5, 144.6, 145.3, 162.4. Anal. 
(C,H,N). 
All the reagents used in the in vitro experiments were of analytical grade and the purity of all the 
compounds tested was > 98% (HPLC detection). 
 
2.2 Animals 
All the animals used in this study (male Wistar rats, Harlan, S. Pietro al Natisone, Italy) were 
treated humanely in accordance with recognised guidelines on experimentation. They had ad 
libitum food and water until the start of the experimental procedure. As few rats as possible were 
used. The purposes and the protocols of our studies have been approved by the Ministero della 
Salute, Rome, Italy. 
 
2.3 NO-release: vasodilator activity 
Thoracic aortas were isolated from male Wistar rats weighing 200-250 g. The endothelium was 
removed and the vessels were helically cut: three strips were obtained from each aorta. The tissues 
were mounted under 1.0 g tension in organ baths containing 30 ml of Krebs-bicarbonate buffer with 
the following composition (mM): NaCl 111.2, KCl 5.0, CaCl2 2.5, MgSO4 1.2, KH2PO4 1.0, 
NaHCO3 12.0, glucose 11.1, maintained at 37°C and gassed with 95% O2 - 5% CO2 (pH = 7.4). The 
aortic strips were allowed to equilibrate for 120 min and then contracted with 1 µM L-
phenylephrine. When the response to the agonist reached a plateau, cumulative concentrations of 
the vasodilating agent were added. The effects of 1 µM ODQ (1H-[1,2,4]-oxadiazolo[4,3-
a]quinoxalin-1-one) on relaxation were evaluated in separate series of experiments in which it was 
added to the organ bath 5 minutes before the contraction. Responses were recorded by an isometric 
transducer connected to the MacLab System PowerLab
®
. Addition of the drug vehicle (DMSO 
maximal amount 0.3%) had no appreciable effect on contraction level. 
 
2.4 Antioxidant properties 
Microsomal membranes from male Wistar rats (200-250 g) were prepared by differential 
centrifugation (8000g, 20 min; 120000g, 1 h) in a HEPES/Sucrose buffer (10 mM, 250 mM, pH = 
7.4) and stored at –80°C. Incubation was performed at 37°C in a Tris-HCl/KCl buffer (100 mM, 
150 mM, pH = 7.4) containing microsomal membranes (2 mg/mL), ascorbic acid (100 µM) and 
DMSO solutions of the tested compounds. An addition of DMSO alone (maximal amount 5%) did 
not significantly change the extent of peroxidation in the control experiments. Lipid peroxidation 
was initiated by adding FeSO4 2.5 µM. Aliquots were taken from the incubation mixture at 5, 15 
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and 30 min and treated with trichloroacetic acid (TCA) 10% p/v. Lipid peroxidation was assessed 
by spectrophotometric (543 nm) determination of the TBARS (2-thiobarbituric acid reactive 
substances) consisting mainly of malondialdehyde (MDA) and TBARS concentrations (expressed 
in nmol/mg protein) were obtained by interpolation with a MDA standard curve [18]. The 
antioxidant activity of tested compounds was evaluated as the % of inhibition of TBARS 
production with respect to control samples, using the plateau values obtained after 30 min of 
incubation.  
 
2.5 Isolated heart preparation 
Six month old Wistar rats were anaesthetised with urethane (1 g/kg intraperitoneally) ten minutes 
after heparin injection. The hearts were rapidly excised and placed in an ice-cold Krebs-Henseleit 
perfusion buffer. Then the aorta was attached to the cannula of the perfusion apparatus and the heart 
was perfused at constant flow with a Krebs solution at 37°C containing NaCl (127 mM), NaHCO3 
(17.7 mM), MgCl2 (1.26 mM), KCl (5.1 mM), CaCl2 (1.5 mM) and glucose (11 mM). Xylocaine 
(10 µg/ml)was added to Krebs solution to prevent the occurrence of arrhythmias (e.g. 
supraventricular tachicardias, ventricular flutter and fibrillation). 
The perfusate buffer was saturated with a 95% O2 and 5% CO2 gas mixture as previously described 
[19, 20]. The constant flow was adjusted with a proper perfusion pump (Watson-Marlow 505DU, 
Falmouth, Cornwall, UK) to obtain a perfusion pressure of 80 mmHg during the stabilization. The 
mean flow to reach this value was (9 ± 1 mL/min/g). A small hole in the left ventricular wall 
allowed drainage of the thebesian flow. 
After 20 minutes of stabilization, each heart underwent 30 minutes of global ischemia, obtained by 
arresting the perfusion pump. Ischemia was followed by 2 hours of reperfusion. At the moment of 
the reperfusion the hearts were infused for 20 min with vehicle (0.1% DMSO) or with studied 
compounds (fig. 1). The protocol was chosen since it has already been shown that a burst of ROS 
occurs during the early reperfusion even when a lack of NO is detected. The treatment started at the 
end of ischemia to mimic the ischemic postconditioning and lasted 20 minutes to include the period 
during which the most injuring effect takes place [18, 19]. 
 
2.6 Infarct size measurement 
At the end of the experiments the hearts were rapidly removed from the perfusion apparatus. After 
isolation of the left ventricle, each heart was cut into 1 mm thick slices. After 20 minutes incubation 
in 0.1% solution of nitro-blue tetrazolium in phosphate buffer, stained viable tissue was separated 
from unstained necrotic tissue and then weighed. The necrotic tissue mass was expressed as a 
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percentage of the total left ventricle mass. The total left ventricle mass also corresponds to the risk 
area because a global ischemia was performed. 
 
2.7 Statistical analysis 
The values of vasodilator activity and infarct size are expressed as mean ± standard error (SE). 
Antioxidant activities are expressed as mean ± 95% CL. One-way analysis of variance and 
Student’s “t” test for unpaired data were used to assess the statistical significance of the changes of 
the studied variables. No difference between the results of the two tests was found. 
 
3. Results 
3.1 Vasodilator activity 
The products were able to relax the denuded rat aortic strips in a dose dependent manner. The 
behaviour of 2 is reported as an example (fig. 2a). Their vasodilator potencies, expressed as EC50, 
namely the molar concentration able to induce 50% of relaxation of the precontracted tissue, are 
reported in Table 1. When the experiments were repeated in the presence of ODQ (1H-[1,2,4]-
oxadiazolo[4,3-a]quinoxalin-1-one), a known inhibitor of the sGC, a strong decrease in the activity 
was observed. 
 
3.2 Antioxidant properties  
Products 1-3 were assessed as inhibitors of ferrous salt/ascorbate induced lipidic peroxidation of 
membrane lipids of rat epatocytes using the TBA (2-thiobarbituric acid) assay. All the products 
were able to inhibit the generation of TBARS in a concentration dependent manner. The behaviour 
of 2 is reported as an example in fig. 2b. The antioxidant potencies expressed as IC50, namely the 
minimal molar concentration able to inhibit 50% of the autoxidation, calculated by non linear 
regression analysis, are reported in Table 1 together with the corresponding values of the reference 
phenol 4 and of the reference NO-donor simple furoxans 1a-3a. 
 
3.3 Infarct size measurement 
Infarct size is expressed as percentage of the left ventricular mass. The effects of compounds 1, 1a 
and 4 given at the concentration of 1 µM and 10 µM are reported in fig. 3. The concentrations were 
chosen inside the range in which the hybrid 1 showed both the NO-donating and antioxidant 
activity. In comparison with the control group (53 ± 3%) at the concentration of 1 µM infarct size 
was significantly reduced by 1 (22 ± 5%, p< 0.001), but not by 1a (37 ± 7%) and 4 (48 ± 8%). On 
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the other hand at 10 µM concentration infarct size was reduced by 4 (24 ± 3%) (p < 0.001), but not 
by 1 (41 ± 7%) and 1a (39 ± 7%) 
The activities of compounds 2, 2a, 3, 3a and 4 were evaluated at 1 µM concentration; in this group 
of compounds only 2 significantly reduced the extension of the infarcted myocardium (33 ± 5%, 
0.01< p < 0.05) (Fig. 4). 
 
4. Discussion 
Analysis of the Table 1 shows that the products 1- 3 behave as potent antioxidants. Their IC50 
values are similar and close to those of the reference phenol 4 and occur at sub µM concentrations. 
By contrast the simple reference furoxans 1a-3a are completely inactive in the concentration range 
in which the aforementioned compounds display radical scavenger actions. Therefore we can 
conclude that the antioxidant activity of the hybrid products are tightly related to the presence into 
their structures of the common phenol moiety.  
In addition, analysis of Table 1 shows that compounds 1 and 2 are potent vasodilators, showing 
EC50 values in the µM concentration range, while 3 is a very potent vasodilator with an EC50 value 
= 4.4 x 10
-8
M. It is generally accepted that the probable vasodilator mechanism of furoxan 
derivatives involves their interaction with endocellular thiols with consequent production of NO, 
which in turns activates soluble guanylate cyclase (sGC) of the vascular smooth muscle cells. This 
activation induces an increase of cyclic guanosine-3,5-monophosphate (cGMP), activation of cGMP 
dependent protein kinase (cGK-1) and finally vasorelaxation [21]. The decrease of the activity 
observed in the presence of ODQ is in keeping with the involvement of NO/cGMP mechanism in 
relaxation. Therefore, the vasodilator potencies of the three hybrids can be reasonably considered a 
measure of their capacity to release NO in a vessel. 
Analysis of Figure 3 evidences that hybrid 1 displays a marked reduction of the infarcted area with 
respect to the control, while the simple furoxan 1a and phenol 4 do not induce any protection when 
tested at 1 µM concentration. A different situation occurred when the experiments were carried out 
at 10 µM concentration. In this case neither 1 nor 1a modified the infarcted size of the control, 
while the simple antioxidant 4 was protective. Since the ability of 1 and 1a to release NO, evaluated 
on the basis of their vasodilator potencies, is similar, this picture suggests that the limitation of the 
infarct area is favoured by an appropriate concentration of NO, and in addition, by the simultaneous 
presence of an antioxidant effect and that these two actions are synergic. This hypothesis seems to 
be reinforced by the similar results we obtained carrying out the experiments at 1 µM concentration 
with products 2 and 2a, which are endowed with NO-mediated vasodilator and antioxidant profiles 
close to those of 1 and 1a. Moreover, working in the same conditions with the most potent NO-
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donors 3 and 3a any protective effects disappear. This overall picture is in keeping with the 
statement that high levels of NO promote apoptosis while basal levels of NO protect 
cardiomyocytes from apoptosis [22]. 
In summary, 1 appears to be a hybrid able to behave as an efficient pharmacological 
postconditioning agent as a consequence of appropriate balance between its NO-donor and 
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Fig.1: Time-line and protocol for ischemia/reperfusion. 


Fig. 2: a Concentration-response curves for vasodilator activity of compound 2 in the absence 
(square) and in the presence (circle) of ODQ. b Effect of compound 2 on time course of lipid 
peroxidation. 

Fig. 3: Extension of the infarct size as a percent of the weight of the left ventricle (% of LV) when 
the compounds 1, 1a and 4 were administered at 1 µM concentration (vertical line filling) and 10 
µM concentration (horizontal line filling). Results are expressed as mean ± SE of 6-9 experiments. 
 

Fig. 4: Extension of the infarct size as a percent of the weight of the left ventricle (% of LV) when 
the compounds 2, 2a, 3, 3a and 4 were administered at 1 µM concentration. Results are expressed 
as mean ± SE of 6-10 experiments. 
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Table I. Antioxidant activity and vasodilator activity of the NO-donor Phenols 1-3, the NO-donor 




(95% CL) (µM)  
EC50 ± SE (µM) 
+ ODQ 1 µM 
EC50 ± SE µM 
1 0.14 (0.14-0.14) [14] 1.5 ± 0.1 [14]
 
19 ± 1 [14]
 
2 0.26 (0.23-0.28) 4.5 ± 0.4 > 30 
a
 
3 0.49 (0.48-0.50) [14] 0.044 ± 0.004 [14]
 
















 [15] 5.6 ± 0.5 [15]
 




 [14] 0.012 ± 0.002 [14]
 
1.2 ± 0.2 [14]
 
4 0.17 (0.16-0.17) [15] - - 
a
 The maximal concentration tested (30 µM due to insolubility limits) cannot reach the 50% of the 
effect. 
b
 The product was inactive in the 2.5 µM – 0.05 µM concentration range. 
